BGLC BioNexus Gene Lab Corp
Services-Medical Laboratories · Nasdaq · SEC CIK 1737523 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-67.3%
TTM net income YoY12.2%
TTM EPS YoY-27.7%
Revenue 3-yr CAGR-32.9%
Net income 3-yr CAGR—
Margins
Gross margin12.3%
Operating margin-81.8%
Net margin-82.4%
FCF margin-27.3%
EBITDA margin-78.2%
Returns
ROE-33.7%
ROA-28.4%
ROIC (approx.)-32.3%
Asset turnover0.34x
Leverage & solvency
Liabilities / assets10.9%
Debt / equity0.00x
Current ratio6.08x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.33x
Accruals ratio-19.1%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $76,156 | $22,842 | $483,760 | $2.54M | $2.26M | $2.14M | $2.52M | $2.63M |
| Cost of revenue | $63,174 | $23,632 | $487,743 | $2.17M | $1.89M | $1.79M | $2.21M | $2.30M |
| Gross profit | $12,982 | -$790 | -$3,983 | $377,685 | $368,022 | $343,493 | $309,234 | $326,536 |
| R&D expense | $13,671 | $14,487 | $11,098 | $14,876 | $12,557 | $12,139 | $17,396 | $10,442 |
| SG&A expense | $298,526 | $327,669 | $181,095 | $445,691 | $516,790 | $391,876 | $165,932 | $792,413 |
| Operating income | -$282,396 | -$540,490 | -$1.03M | -$702,509 | -$611,293 | -$618,418 | -$416,220 | -$1.34M |
| Interest expense | — | — | — | — | — | — | — | $6,193 |
| Pretax income | -$286,451 | -$543,575 | -$1.04M | -$708,991 | -$616,172 | -$623,327 | -$422,032 | -$1.34M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | -$80,701 | $1,555 |
| Net income | -$286,451 | -$543,575 | -$1.04M | -$708,991 | -$616,172 | -$623,327 | -$348,319 | -$1.35M |
| EBITDA | -$254,331 | -$512,197 | -$1.00M | -$673,508 | -$583,493 | -$591,776 | -$386,671 | -$1.26M |
| EPS (diluted) | -0.12 | -0.23 | — | -0.40 | -0.34 | -0.35 | — | -0.75 |
| Weighted avg. shares (diluted) | 2.42M | 2.42M | — | 1.80M | 1.80M | 1.80M | — | 1.80M |
| Banking | ||||||||
| Net interest income | — | — | — | — | — | — | — | $2,429 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.23M | $1.34M | $2.38M | $1.15M | $1.54M | $2.09M | $2.89M | $4.14M |
| Receivables | $15,544 | $79,860 | $505,885 | $1.52M | $1.85M | — | $1.38M | — |
| Inventory | $652,892 | $667,154 | $676,703 | $1.01M | $1.22M | $1.18M | $1.39M | $1.39M |
| Current assets | $4.94M | $5.20M | $5.45M | $5.63M | $6.38M | $6.54M | $7.43M | $7.04M |
| PP&E, net | $1.54M | $1.58M | $1.60M | $1.57M | $1.59M | $1.52M | $1.52M | $1.73M |
| Total assets | $8.73M | $9.04M | $9.25M | $7.62M | $9.42M | $9.48M | $10.43M | $11.00M |
| Current liabilities | $812,938 | $796,470 | $520,957 | $678,023 | $1.76M | $1.56M | $1.95M | $1.41M |
| Total liabilities | $947,981 | $946,877 | $637,856 | $804,966 | $1.90M | $1.71M | $2.11M | $1.61M |
| Shareholders' equity | $7.78M | $8.09M | $8.61M | $6.82M | $7.52M | $7.77M | $8.32M | $9.39M |
| Shares outstanding | 2.42M | 2.42M | 2.42M | 1.80M | 1.80M | 17.97M | 1.80M | 17.97M |
| Cash flow statement | ||||||||
| Operating cash flow | -$422,491 | -$147,671 | $961,062 | -$1.24M | -$737,907 | -$824,072 | $219,203 | -$1.60M |
| Capital expenditure | $250 | $325 | $977 | $5,483 | $21,459 | $9,052 | $4,022 | $199,189 |
| Free cash flow | -$422,741 | -$147,996 | $960,085 | -$1.24M | -$759,366 | -$833,124 | $215,181 | -$1.80M |
| Investing cash flow | $416,140 | -$13,988 | -$5,717 | $994,646 | -$28,532 | -$15,646 | $494,158 | -$203,160 |
| Financing cash flow | $13,607 | $59,709 | $266,544 | $34,187 | -$1,030 | -$860 | -$142,387 | -$55,982 |
| Depreciation & amortization | $28,065 | $28,293 | $28,430 | $29,001 | $27,800 | $26,642 | $29,549 | $74,611 |
| Stock-based compensation | — | — | $794,770 | — | — | — | $0 | — |
Free plan shows the latest 8 periods; Pro shows all 34 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.